{"id":"https://openalex.org/W2000756020","doi":"https://doi.org/10.1158/1535-7163.mct-07-2070","title":"Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models","display_name":"Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models","publication_year":2008,"publication_date":"2008-02-01","ids":{"openalex":"https://openalex.org/W2000756020","doi":"https://doi.org/10.1158/1535-7163.mct-07-2070","mag":"2000756020","pmid":"https://pubmed.ncbi.nlm.nih.gov/18281523"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-07-2070","doi":"https://doi.org/10.1158/1535-7163.mct-07-2070","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-07-2070","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009937027","display_name":"Shining Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I84392919","display_name":"Temple University","ror":"https://ror.org/00kx1jb78","country_code":"US","type":"education","lineage":["https://openalex.org/I84392919"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shining Wang","raw_affiliation_strings":["Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania","Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I84392919"]},{"raw_affiliation_string":"Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA","institution_ids":["https://openalex.org/I84392919"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100428921","display_name":"Ping Guo","orcid":"https://orcid.org/0000-0003-4901-334X","observed_orcids":["https://orcid.org/0000-0003-4901-334X"]},"institutions":[{"id":"https://openalex.org/I84392919","display_name":"Temple University","ror":"https://ror.org/00kx1jb78","country_code":"US","type":"education","lineage":["https://openalex.org/I84392919"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ping Guo","raw_affiliation_strings":["Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I84392919"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100413307","display_name":"Xiaomin Wang","orcid":"https://orcid.org/0000-0003-1274-224X","observed_orcids":["https://orcid.org/0000-0003-1274-224X","https://orcid.org/0009-0005-5235-4710"]},"institutions":[{"id":"https://openalex.org/I84392919","display_name":"Temple University","ror":"https://ror.org/00kx1jb78","country_code":"US","type":"education","lineage":["https://openalex.org/I84392919"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaomin Wang","raw_affiliation_strings":["Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I84392919"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052503472","display_name":"Qingyu Stephanie Zhou","orcid":"https://orcid.org/0000-0002-4389-1582","observed_orcids":["https://orcid.org/0000-0002-4389-1582"]},"institutions":[{"id":"https://openalex.org/I84392919","display_name":"Temple University","ror":"https://ror.org/00kx1jb78","country_code":"US","type":"education","lineage":["https://openalex.org/I84392919"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qingyu Zhou","raw_affiliation_strings":["Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I84392919"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056500955","display_name":"James M. Gallo","orcid":"https://orcid.org/0000-0003-1553-4817","observed_orcids":["https://orcid.org/0000-0003-1553-4817"]},"institutions":[{"id":"https://openalex.org/I84392919","display_name":"Temple University","ror":"https://ror.org/00kx1jb78","country_code":"US","type":"education","lineage":["https://openalex.org/I84392919"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James M. Gallo","raw_affiliation_strings":["Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I84392919"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I84392919"],"apc_list":null,"apc_paid":null,"fwci":4.7014,"has_fulltext":false,"cited_by_count":58,"citation_normalized_percentile":{"value":0.94481696,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"7","issue":"2","first_page":"407","last_page":"417"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8202999830245972,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8202999830245972,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.06700000166893005,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.02319999970495701,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.8379999995231628},{"id":"https://openalex.org/keywords/pharmacokinetic-pharmacodynamic-modeling","display_name":"pharmacokinetic-pharmacodynamic modeling","score":0.8230000138282776},{"id":"https://openalex.org/keywords/egfrviii-mutation","display_name":"EGFRvIII mutation","score":0.7860000133514404},{"id":"https://openalex.org/keywords/pharmacogenetics","display_name":"pharmacogenetics","score":0.859000027179718},{"id":"https://openalex.org/keywords/erk1-2-phosphorylation","display_name":"ERK1/2 phosphorylation","score":0.8019999861717224},{"id":"https://openalex.org/keywords/targeted-anticancer-drugs","display_name":"targeted anticancer drugs","score":0.6000000238418579}],"concepts":[{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.9404782056808472},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7263461351394653},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6780086755752563},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6284009218215942},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5120556950569153},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.45868515968322754},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4408606290817261},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.43651649355888367},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.43176668882369995},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38478052616119385},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.37754806876182556},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3406526744365692},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2687753438949585},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.23369696736335754},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077156","descriptor_name":"Gefitinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D010597","descriptor_name":"Pharmacogenetics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-07-2070","doi":"https://doi.org/10.1158/1535-7163.mct-07-2070","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-07-2070","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:18281523","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18281523","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3577069034","display_name":"Cells Designed to Deliver Anticancer Drugs by Apoptosis","funder_award_id":"R01CA085577","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G464542450","display_name":null,"funder_award_id":"CA72937","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G662236807","display_name":null,"funder_award_id":"CA 85577","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G7349805395","display_name":"Interactions Between Cytotoxic and Antiangiogenic Drugs","funder_award_id":"R01CA072937","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W1515666340","https://openalex.org/W1523413020","https://openalex.org/W1587017865","https://openalex.org/W1659692600","https://openalex.org/W1967330952","https://openalex.org/W1987797739","https://openalex.org/W1997914859","https://openalex.org/W2037211078","https://openalex.org/W2042103473","https://openalex.org/W2043696829","https://openalex.org/W2065521652","https://openalex.org/W2070705072","https://openalex.org/W2074642772","https://openalex.org/W2101697551","https://openalex.org/W2103962487","https://openalex.org/W2107055927","https://openalex.org/W2107065429","https://openalex.org/W2109689528","https://openalex.org/W2113045978","https://openalex.org/W2120718661","https://openalex.org/W2124363887","https://openalex.org/W2125110978","https://openalex.org/W2125395336","https://openalex.org/W2138291384","https://openalex.org/W2139671097","https://openalex.org/W2150037470","https://openalex.org/W2152780528","https://openalex.org/W2154670277","https://openalex.org/W2155977433","https://openalex.org/W2161821474","https://openalex.org/W2163402367","https://openalex.org/W2167778021","https://openalex.org/W2171338194"],"related_works":["https://openalex.org/W3134497505","https://openalex.org/W2012332584","https://openalex.org/W2519978239","https://openalex.org/W4393034753","https://openalex.org/W4400272365","https://openalex.org/W3141287186","https://openalex.org/W2265442695","https://openalex.org/W2416777431","https://openalex.org/W1986846638","https://openalex.org/W2267710198"],"abstract_inverted_index":{"Epidermal":[0],"growth":[1],"factor":[2],"receptor":[3],"(EGFR)":[4],"inhibitors,":[5],"such":[6],"as":[7,113],"gefitinib,":[8],"are":[9],"examples":[10],"of":[11,39,72,92,117,155,202,227,236],"targeted":[12],"anticancer":[13],"drugs":[14],"whose":[15],"drug":[16,162,169,245,253],"sensitivity":[17],"is":[18],"related":[19],"to":[20,29,43,55,132,216,248],"gene":[21],"mutations":[22],"that":[23,51,129,222],"adds":[24],"a":[25,125,135,156,165,174],"pharmacogenetic":[26],"(PG)":[27],"dimension":[28],"any":[30],"pharmacokinetic":[31],"(PK)":[32],"and":[33,99,108,173,247],"pharmacodynamic":[34],"(PD)":[35],"analysis.":[36],"The":[37,233],"goal":[38],"this":[40,69],"investigation":[41],"was":[42,130],"cast":[44],"the":[45,160,182,199,203,206],"combined":[46],"PG/PK/PD":[47],"variables":[48],"into":[49],"models":[50,146],"could":[52,241],"be":[53,242],"used":[54],"design":[56],"equivalent":[57,224,238],"PK/PD":[58,145,207,237],"dosing":[59,239],"regimens":[60,219,240],"for":[61,149,209,220],"gefitinib":[62,89,106,221],"in":[63,134,138,171,181,189,229,244,252],"genetically":[64],"distinct":[65],"tumor":[66,109,140,151,166,191,211,231],"models.":[67],"To":[68],"end,":[70],"groups":[71],"mice":[73],"bearing":[74],"either":[75],"s.c.":[76],"LN229-wild-type":[77],"EGFR":[78,84,200],"or":[79],"LN229-EGFRvIII":[80],"mutant":[81],"tumors,":[82],"an":[83],"inhibitor-sensitizing":[85],"mutation,":[86],"were":[87,111,114,147,214],"given":[88],"at":[90],"doses":[91],"10":[93],"mg/kg":[94,97,101],"i.v.,":[95],"50":[96],"intraarterially,":[98],"150":[100],"p.o.":[102],"In":[103],"each":[104,139,150,190,210,230],"group,":[105],"plasma":[107,161],"concentrations":[110],"quantitated,":[112],"tumoral":[115],"amounts":[116],"phosphorylated":[118],"extracellular":[119],"signal-regulated":[120],"kinase":[121],"(ERK)":[122],"1/2":[123],"(pERK),":[124],"PD":[126,177,195,225],"end":[127],"point":[128],"shown":[131],"respond":[133],"dose-dependent":[136],"manner":[137],"type.":[141,232],"Hybrid":[142],"physiologically":[143],"based":[144],"developed":[148],"type,":[152,212],"which":[153],"consisted":[154],"forcing":[157],"function":[158],"describing":[159],"concentration":[163],"profile,":[164],"compartment":[167],"depicting":[168],"disposition":[170],"tumor,":[172],"mechanistic":[175],"target-response":[176],"model":[178,208],"characterizing":[179],"pERK":[180,228],"tumor.":[183],"Gefitinib":[184],"showed":[185],"analogous":[186],"PK":[187],"properties":[188],"type":[192],"yet":[193],"different":[194],"characteristics":[196],"consistent":[197],"with":[198],"status":[201],"tumors.":[204],"Using":[205],"simulations":[213],"done":[215],"define":[217],"multiple-dose":[218],"yielded":[223],"profiles":[226],"novel":[234],"concept":[235],"applied":[243],"development":[246],"delineate":[249],"PG":[250],"differences":[251],"activity.":[254]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}